A new reward premium system, “Reward Premiums for the Promotion of Innovative Drug Discovery and Resolution of Off-label Use Issue, etc,” unique to Japan, was introduced in 2010 and was used in 2010, 2012, and 2014. If the new rewards system is applied to a drug, the company can recover costs early and reinvest in research and development of unapproved or innovative drugs. However, a detailed analysis of the drugs to which this new system was applied has not been conducted. In this study, a data analysis was performed to determine what factors were strongly associated with receiving a reward. Domestic pharmaceuticals in the top 500 sales in September 2009, 2011, and 2013 were selected for this study. Multivariable or univariate logistic regression was performed. The following factors were significantly related to receiving a reward: a more recent launch, a global promotional company, and orphan drug designation. Cardiovascular drugs were less likely to receive rewards, whereas drugs acting on the central nervous system, anticancer agents, and immunomodulatory agents were significantly more likely to receive rewards. These findings suggest that orphan drugs and drugs with specific Anatomical Therapeutic Chemical (ATC) classifications such as N and L are likely to receive rewards. We can verify that this incentive program works well in Japan, launching truly innovative drugs that meet high medical needs.
1 January 2016 in Therapeutic Innovation & Regulatory Science
A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.
1 March 2016 in Therapeutic Innovation & Regulatory Science
We characterized mice administered corticosterone (CORT) at a dose of 20 mg/kg for 3 weeks to determine their suitability as a model of mood disorders and found that the time immobilized in the tail suspension test was longer and the time spent in the open arms of the elevated plus‐maze test was shorter than those of the vehicle‐treated group, findings demonstrating that chronic CORT induced both depression‐like and anxiety‐like behaviors. Furthermore, the levels of phosphorylated extracellular signal‐regulated kinase (pERK) 1/2 in the hippocampus and cerebral cortex were reduced in the CORT‐treated group. Using this model, we investigated the protective effect of the ester, thioester, and amide compounds of 2‐decenoic acid derivatives (termed compounds A, B, and C, respectively). The potency of the protective activity against the CORT‐induced depression‐like or anxiety‐like behaviors and the reduction in pERK1/2 level were found to be in the following order: compound B > compound C > compound A. Therefore, we further investigated the therapeutic activity of only compound B, and its effect on depression‐like behavior was observed after oral administration for 1 or 2 weeks, and its effect on anxiety‐like behavior was observed after oral administration for 3 weeks. The ratios of phosphorylated ERK1/2, Akt, and cAMP‐response element‐binding protein to their respective nonphosphorylated forms were smaller in the CORT‐treated group than in the vehicle‐treated group; however, subsequent treatment with compound B at either 0.3 or 1.5 mg/kg significantly ameliorated this reduction. Compound B appeared to elicit intracellular signaling, similar to that elicited by brain‐derived neurotrophic factor, and its mode of action was shown to be novel and different from that of fluvoxamine, a currently prescribed drug for mood disorders.